Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.36 |
| ▸ | EDNRA | P25101 | 3/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884939 | 0.81 | OPRL1 (0.36) | OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL2882445 | 0.81 | OPRL1 (0.40) | OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL2882638 | 0.78 | OPRL1 (0.33) | OPRL1KCNH2EDNRAALDH1A1 | |
| SCHEMBL2882647 | 0.78 | OPRL1 (0.33) | OPRL1KCNH2EDNRAALDH1A1 | |
| SCHEMBL2884890 | 0.78 | OPRL1 (0.33) | OPRL1KCNH2EDNRAALDH1A1 | |
| SCHEMBL13978036 | 0.72 | CYP2D6 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15727900 | 0.71 | CYP2D6 (0.43) | ALDH1A1 | |
| SCHEMBL2882896 | 0.71 | OPRL1 (0.51) | OPRL1EDNRAALDH1A1 | |
| SCHEMBL2881932 | 0.71 | KMT2A (0.32) | OPRL1EDNRAALDH1A1 | |
| SCHEMBL7719725 | 0.71 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885EDNRA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.